This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
by Zacks Equity Research
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
by Zacks Equity Research
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Top Stock Reports for Walmart, Pfizer & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Charter Communications (CHTR).
Lilly Expects No Drug Supply Shortages Due to Coronavirus
by Zacks Equity Research
Lilly (LLY) does not expect shortage in supply of its medicines as it does not source APIs of any of its marketed drugs from China.
Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA
by Zacks Equity Research
Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.
The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis
This is Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength
by Zacks Equity Research
Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.
Top Stock Reports for Eli Lilly, Union Pacific & Lockheed
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Union Pacific (UNP) and Lockheed Martin (LMT).
Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
by Kinjel Shah
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics (UTHR) misses fourth-quarter estimates on both fronts. Stock declines in response.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Lilly Reports Disappointing Data on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, United Parcel Service, Microsoft and Nike
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, United Parcel Service, Microsoft and Nike